Discovery of a novel B-raf fusion protein related to c-met drug resistance

Roslyn Dillon, Carol L. Nilsson, Stone D H Shi, Nathan V. Lee, Bryan Krastins, Michael J. Greig

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In recent years, there have been notable advances with the development of anticancer drugs including those targeting protein tyrosine kinases such as the c-Met receptor, which has been implicated in the development and progression of several cancers. However, despite such progress, drug resistance continues to be the single most important cause of cancer treatment failure, and understanding the mechanisms of drug resistance remains a major hurdle in treating patients with recurrent disease. PF-04217903 is a small-molecule c-Met kinase inhibitor that potently inhibits c-Met-driven processes such as cell growth (proliferation and survival), motility, invasion, and morphology of a variety of tumor cells. Resistance to PF-04217903 was observed in GTL-16, a gastric carcinoma cell line with a constitutively activated c-Met receptor. In this report, mass spectrometry (MS) based quantitative phosphoproteomic analysis was used to determine changes in signaling pathways in the parental cells in response to c-Met inhibition and to investigate the changes in protein levels and related canonical pathways in both parental and PF-04217903 resistant (R3) clones in response to c-Met inhibition. The quantitative MS workflow included phosphoprotein enrichment of cell lysates from six treatment conditions: in-solution digestion, chemical labeling of peptides with a set of 6-plex isobaric tandem mass tags (TMT), HILIC fractionation, phosphopeptide enrichment, and nano LC-MS/MS on a LTQ-Orbitrap mass spectrometer. An investigation of these quantitative datasets using Ingenuity Pathways Analysis (IPA) revealed pathway changes in the various treatments that were consistent with previously observed transcriptomic and phenotypic changes. Proteomic analysis also revealed an increase in B-Raf expression in R3 clones. Expression profiling confirmed that B-Raf gene copy number was up-regulated and also indicated the presence of a mutated form of B-Raf. Using a bottom-up MS approach, SND-1 was identified as the B-Raf fusion partner. The discovery of this novel B-Raf fusion protein presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors.

Original languageEnglish (US)
Pages (from-to)5084-5094
Number of pages11
JournalJournal of Proteome Research
Volume10
Issue number11
DOIs
StatePublished - Nov 4 2011

Fingerprint

Drug Resistance
Mass spectrometry
Mass Spectrometry
Fusion reactions
Clone Cells
Pharmaceutical Preparations
Phosphopeptides
Neoplasms
Proteins
Gene Dosage
Workflow
Phosphoproteins
Tandem Mass Spectrometry
Treatment Failure
Proteomics
Protein-Tyrosine Kinases
Cells
Digestion
Cell Survival
Stomach

Keywords

  • B-Raf
  • c-Met
  • drug resistance
  • gastric cancer
  • GTL-16
  • LC-MS/MS
  • mass spectrometry
  • phosphopeptide enrichment
  • phosphoproteomics
  • SND1

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Dillon, R., Nilsson, C. L., Shi, S. D. H., Lee, N. V., Krastins, B., & Greig, M. J. (2011). Discovery of a novel B-raf fusion protein related to c-met drug resistance. Journal of Proteome Research, 10(11), 5084-5094. https://doi.org/10.1021/pr200498v

Discovery of a novel B-raf fusion protein related to c-met drug resistance. / Dillon, Roslyn; Nilsson, Carol L.; Shi, Stone D H; Lee, Nathan V.; Krastins, Bryan; Greig, Michael J.

In: Journal of Proteome Research, Vol. 10, No. 11, 04.11.2011, p. 5084-5094.

Research output: Contribution to journalArticle

Dillon, R, Nilsson, CL, Shi, SDH, Lee, NV, Krastins, B & Greig, MJ 2011, 'Discovery of a novel B-raf fusion protein related to c-met drug resistance', Journal of Proteome Research, vol. 10, no. 11, pp. 5084-5094. https://doi.org/10.1021/pr200498v
Dillon R, Nilsson CL, Shi SDH, Lee NV, Krastins B, Greig MJ. Discovery of a novel B-raf fusion protein related to c-met drug resistance. Journal of Proteome Research. 2011 Nov 4;10(11):5084-5094. https://doi.org/10.1021/pr200498v
Dillon, Roslyn ; Nilsson, Carol L. ; Shi, Stone D H ; Lee, Nathan V. ; Krastins, Bryan ; Greig, Michael J. / Discovery of a novel B-raf fusion protein related to c-met drug resistance. In: Journal of Proteome Research. 2011 ; Vol. 10, No. 11. pp. 5084-5094.
@article{eb1525570db34755be0afbd93cda5bb3,
title = "Discovery of a novel B-raf fusion protein related to c-met drug resistance",
abstract = "In recent years, there have been notable advances with the development of anticancer drugs including those targeting protein tyrosine kinases such as the c-Met receptor, which has been implicated in the development and progression of several cancers. However, despite such progress, drug resistance continues to be the single most important cause of cancer treatment failure, and understanding the mechanisms of drug resistance remains a major hurdle in treating patients with recurrent disease. PF-04217903 is a small-molecule c-Met kinase inhibitor that potently inhibits c-Met-driven processes such as cell growth (proliferation and survival), motility, invasion, and morphology of a variety of tumor cells. Resistance to PF-04217903 was observed in GTL-16, a gastric carcinoma cell line with a constitutively activated c-Met receptor. In this report, mass spectrometry (MS) based quantitative phosphoproteomic analysis was used to determine changes in signaling pathways in the parental cells in response to c-Met inhibition and to investigate the changes in protein levels and related canonical pathways in both parental and PF-04217903 resistant (R3) clones in response to c-Met inhibition. The quantitative MS workflow included phosphoprotein enrichment of cell lysates from six treatment conditions: in-solution digestion, chemical labeling of peptides with a set of 6-plex isobaric tandem mass tags (TMT), HILIC fractionation, phosphopeptide enrichment, and nano LC-MS/MS on a LTQ-Orbitrap mass spectrometer. An investigation of these quantitative datasets using Ingenuity Pathways Analysis (IPA) revealed pathway changes in the various treatments that were consistent with previously observed transcriptomic and phenotypic changes. Proteomic analysis also revealed an increase in B-Raf expression in R3 clones. Expression profiling confirmed that B-Raf gene copy number was up-regulated and also indicated the presence of a mutated form of B-Raf. Using a bottom-up MS approach, SND-1 was identified as the B-Raf fusion partner. The discovery of this novel B-Raf fusion protein presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors.",
keywords = "B-Raf, c-Met, drug resistance, gastric cancer, GTL-16, LC-MS/MS, mass spectrometry, phosphopeptide enrichment, phosphoproteomics, SND1",
author = "Roslyn Dillon and Nilsson, {Carol L.} and Shi, {Stone D H} and Lee, {Nathan V.} and Bryan Krastins and Greig, {Michael J.}",
year = "2011",
month = "11",
day = "4",
doi = "10.1021/pr200498v",
language = "English (US)",
volume = "10",
pages = "5084--5094",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Discovery of a novel B-raf fusion protein related to c-met drug resistance

AU - Dillon, Roslyn

AU - Nilsson, Carol L.

AU - Shi, Stone D H

AU - Lee, Nathan V.

AU - Krastins, Bryan

AU - Greig, Michael J.

PY - 2011/11/4

Y1 - 2011/11/4

N2 - In recent years, there have been notable advances with the development of anticancer drugs including those targeting protein tyrosine kinases such as the c-Met receptor, which has been implicated in the development and progression of several cancers. However, despite such progress, drug resistance continues to be the single most important cause of cancer treatment failure, and understanding the mechanisms of drug resistance remains a major hurdle in treating patients with recurrent disease. PF-04217903 is a small-molecule c-Met kinase inhibitor that potently inhibits c-Met-driven processes such as cell growth (proliferation and survival), motility, invasion, and morphology of a variety of tumor cells. Resistance to PF-04217903 was observed in GTL-16, a gastric carcinoma cell line with a constitutively activated c-Met receptor. In this report, mass spectrometry (MS) based quantitative phosphoproteomic analysis was used to determine changes in signaling pathways in the parental cells in response to c-Met inhibition and to investigate the changes in protein levels and related canonical pathways in both parental and PF-04217903 resistant (R3) clones in response to c-Met inhibition. The quantitative MS workflow included phosphoprotein enrichment of cell lysates from six treatment conditions: in-solution digestion, chemical labeling of peptides with a set of 6-plex isobaric tandem mass tags (TMT), HILIC fractionation, phosphopeptide enrichment, and nano LC-MS/MS on a LTQ-Orbitrap mass spectrometer. An investigation of these quantitative datasets using Ingenuity Pathways Analysis (IPA) revealed pathway changes in the various treatments that were consistent with previously observed transcriptomic and phenotypic changes. Proteomic analysis also revealed an increase in B-Raf expression in R3 clones. Expression profiling confirmed that B-Raf gene copy number was up-regulated and also indicated the presence of a mutated form of B-Raf. Using a bottom-up MS approach, SND-1 was identified as the B-Raf fusion partner. The discovery of this novel B-Raf fusion protein presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors.

AB - In recent years, there have been notable advances with the development of anticancer drugs including those targeting protein tyrosine kinases such as the c-Met receptor, which has been implicated in the development and progression of several cancers. However, despite such progress, drug resistance continues to be the single most important cause of cancer treatment failure, and understanding the mechanisms of drug resistance remains a major hurdle in treating patients with recurrent disease. PF-04217903 is a small-molecule c-Met kinase inhibitor that potently inhibits c-Met-driven processes such as cell growth (proliferation and survival), motility, invasion, and morphology of a variety of tumor cells. Resistance to PF-04217903 was observed in GTL-16, a gastric carcinoma cell line with a constitutively activated c-Met receptor. In this report, mass spectrometry (MS) based quantitative phosphoproteomic analysis was used to determine changes in signaling pathways in the parental cells in response to c-Met inhibition and to investigate the changes in protein levels and related canonical pathways in both parental and PF-04217903 resistant (R3) clones in response to c-Met inhibition. The quantitative MS workflow included phosphoprotein enrichment of cell lysates from six treatment conditions: in-solution digestion, chemical labeling of peptides with a set of 6-plex isobaric tandem mass tags (TMT), HILIC fractionation, phosphopeptide enrichment, and nano LC-MS/MS on a LTQ-Orbitrap mass spectrometer. An investigation of these quantitative datasets using Ingenuity Pathways Analysis (IPA) revealed pathway changes in the various treatments that were consistent with previously observed transcriptomic and phenotypic changes. Proteomic analysis also revealed an increase in B-Raf expression in R3 clones. Expression profiling confirmed that B-Raf gene copy number was up-regulated and also indicated the presence of a mutated form of B-Raf. Using a bottom-up MS approach, SND-1 was identified as the B-Raf fusion partner. The discovery of this novel B-Raf fusion protein presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors.

KW - B-Raf

KW - c-Met

KW - drug resistance

KW - gastric cancer

KW - GTL-16

KW - LC-MS/MS

KW - mass spectrometry

KW - phosphopeptide enrichment

KW - phosphoproteomics

KW - SND1

UR - http://www.scopus.com/inward/record.url?scp=80655131098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80655131098&partnerID=8YFLogxK

U2 - 10.1021/pr200498v

DO - 10.1021/pr200498v

M3 - Article

C2 - 21936566

AN - SCOPUS:80655131098

VL - 10

SP - 5084

EP - 5094

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 11

ER -